U.S. Markets closed

Revance Stock Loses 39% Of Its Value After FDA Rejects Its Frown Lines Injection

·2 min read
Revance Stock Loses 39% Of Its Value After FDA Rejects Its Frown Lines Injection
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The FDA rejected Revance Therapeutics' frown lines treatment, depressing RVNC stock which fell to an 18-month low on Monday.